Birch pollen allergy immunotherapy - LETI Pharma

Drug Profile

Birch pollen allergy immunotherapy - LETI Pharma

Alternative Names: Depigmented Glutaraldehyde Polymerized Birch Pollen Allergenic Extract; Depigoid Birch; Depigoid Birch 5000

Latest Information Update: 09 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LETI Pharma GmbH
  • Class Allergens; Antiallergics; Tree pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Rhinoconjunctivitis; Seasonal allergic rhinitis
  • No development reported Atopic dermatitis

Most Recent Events

  • 09 Oct 2015 No recent reports on development identified - Phase-III for Rhinoconjunctivitis (In adolescents, In children, In adults) in Sweden (SC)
  • 09 Oct 2015 No recent reports on development identified - Phase-III for Seasonal allergic rhinitis (In adolescents, In children, In adults) in Sweden (SC)
  • 14 Aug 2015 No recent reports on development identified - Phase-II for Atopic dermatitis in Germany (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top